Asthma

Community pharmacists boost asthma control by improving adherence, inhaler technique, and access—cutting exacerbations and emergency department visits.

New AAAAI data spotlight oral remibrutinib for CSU, next-generation peanut allergy therapies, infant microbiome prevention, and GLP‑1 receptor agonists linked to fewer asthma flares.

VOYAGE trial data show dupilumab improves pediatric asthma control and lowers exacerbations versus placebo, with higher remission and lung function gains earlier.

Research reveals that patients with asthma who experience symptoms of depression show elevated BDNF levels, suggesting unique biological links between asthma severity and depressive symptoms.

New research reveals how specific gut bacteria in infants may reduce the risk of allergies and asthma, offering potential preventive strategies.

Collaborative health care efforts are needed to effectively manage asthma, and pharmacists play a key role in optimizing asthma treatment plans.

Research reveals that wildfire smoke exposure significantly impacts pediatric asthma control in the northeastern US, highlighting urgent climate health concerns.

Researchers uncover how type 2 innate lymphoid (ILC2) and T helper 2 (Th2) cells in allergic asthma survive toxic environments, revealing potential new therapeutic strategies for treatment.

The FDA approves depemokimab-ulaa as a long-acting treatment for severe asthma, enhancing patient care with fewer injections and improved outcomes.

A study reveals that many asthma patients switch biologics due to perceived ineffectiveness, highlighting the need for personalized treatment strategies.

The FDA approves Amneal's albuterol sulfate inhalation aerosol, enhancing access to vital asthma and COPD treatments for millions of Americans.

Infants hospitalized with respiratory syncytial virus (RSV) bronchiolitis who were born to parents with asthma had a significantly higher risk of later developing asthma, the investigators found.

Thunderstorms significantly increase asthma-related emergency visits, highlighting the need for storm-specific preparedness and management strategies for patients.

The findings from the BATURA clinical trial were presented at the 2025 ACAAI Annual Scientific Meeting.

Depemokimab shows significant improvements in asthma symptoms and peak expiratory flow, supporting its twice-yearly use for severe asthma management.

Home monitoring enhances pediatric asthma management, boosting patient engagement and awareness while providing valuable medical feedback for better control.

These findings are from the WAYFINDER clinical trial and were presented at the CHEST 2025 Annual Meeting.

A new low-carbon albuterol inhaler shows therapeutic equivalence to original options, suggesting reduced emissions and improved sustainability for patients with asthma and other respiratory conditions.

Higher levels of cyclic adenosine monophosphate (cAMP) may be key to diagnosing asthma and its severity as well as monitoring patients.

Research highlights the effectiveness of the albuterol-budesonide combination for ensuring rapid relief and safety in patients with asthma.

BATURA demonstrated that albuterol/budesonide significantly reduced severe exacerbation risk reduction in patients with mild asthma.

COVID-19 vaccination significantly reduces the risk of asthma and other airway inflammatory diseases, offering vital protection against respiratory complications.

The "farm effect" is a term researchers use to describe the protective impact of growing up on traditional farms—especially around livestock, barns, and raw farm environments—on the development of allergies and asthma.

New research uncovers complex inflammatory pathways driving asthma flare-ups in children, highlighting the need for personalized treatment strategies.

Even patients who are confident in their abilities often use incorrect technique